Survival after a blood clot in the liver depends heavily on which vessel is blocked, how quickly treatment starts, and whether the liver was already diseased. For portal vein thrombosis caught early and without bowel involvement, the outlook is generally favorable, especially with prompt anticoagulation. For Budd-Chiari syndrome, which blocks the hepatic veins draining blood out of the liver, five-year survival ranges from roughly 42% in severe cases to 89% in mild ones, according to a large prognostic study. These are two distinct conditions with overlapping symptoms, and understanding the differences matters for making sense of the numbers.
Two Conditions, Two Sets of Veins
When people talk about a “blood clot in the liver,” they are usually referring to one of two things. Portal vein thrombosis (PVT) is a clot in the portal vein, the large vessel that carries nutrient-rich blood from the intestines into the liver. Budd-Chiari syndrome (BCS) involves clots in the hepatic veins, which carry blood out of the liver and back toward the heart. The distinction is not academic: the symptoms, complications, and treatment strategies differ, and so do survival rates. At least two of the three main hepatic veins must be blocked before clinically obvious Budd-Chiari syndrome develops.1PubMed Central. Budd-Chiari syndrome: etiology, pathogenesis and diagnosis
PVT can happen in people with otherwise healthy livers or in those who already have cirrhosis. BCS tends to strike younger adults and is driven by blood-clotting disorders. Both conditions can present acutely, with sudden onset, or develop slowly over months or years with milder symptoms that build gradually.
Recognizing the Symptoms
Acute portal vein thrombosis tends to announce itself with abdominal pain, nausea, vomiting, and sometimes fever. If the clot extends into the veins draining the intestines, intestinal congestion and bleeding can occur.2GastroenterologÃa y HepatologÃa (English Edition). Treatment of non-cirrhotic, non-tumoural portal vein thrombosis When PVT becomes chronic, the acute symptoms fade and the main problems stem from elevated pressure in the portal system: fluid buildup in the abdomen (ascites), an enlarged spleen, and swollen veins in the esophagus or stomach that can bleed.
Budd-Chiari syndrome shares some of these features but has its own hallmarks. The classic triad is abdominal pain, an enlarged liver, and ascites. However, up to about one in five people with BCS have no obvious symptoms at all, a pattern seen when the blockage develops slowly enough for the body to build alternative drainage pathways around the obstructed veins.3Postgraduate Medical Journal. Budd–Chiari syndrome: investigation, treatment and outcomes That silent progression can make early detection difficult.
Causes and Risk Factors
The single largest category of causes is blood disorders that make clotting more likely. Myeloproliferative neoplasms, conditions where the bone marrow overproduces blood cells, are the most common underlying cause of both PVT and BCS when no cirrhosis or cancer is present. These disorders are found in close to 40% of patients with either condition.4PubMed. Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies A specific genetic mutation called JAK2 V617F is frequently identified in these patients and plays a direct role in triggering the clots.5PubMed Central. JAK2 V617F Mutation Leading to Portal Vein Thrombosis in a Young Patient: A Case Report
In Budd-Chiari syndrome specifically, some form of clotting abnormality can be found in about three-quarters of patients, and more than one contributing factor is present in roughly a quarter of cases.1PubMed Central. Budd-Chiari syndrome: etiology, pathogenesis and diagnosis Beyond blood disorders, other risk factors include oral contraceptive use, pregnancy, abdominal infections, inflammatory bowel disease, and liver cancer. For PVT in people with cirrhosis, the sluggish portal blood flow caused by the scarred liver is itself a major contributor.
How Doctors Find and Characterize Liver Clots
Ultrasound with Doppler imaging is usually the first test ordered when a clot is suspected, because it is fast, widely available, and does not involve radiation. Contrast-enhanced ultrasound can be remarkably effective: in one study comparing it head-to-head with CT scanning in liver-cancer patients, contrast ultrasound detected all 50 portal vein clots and correctly identified their nature in 98% of cases, while CT detected only 68% and correctly characterized 68% of those it found.6PubMed. Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma
Characterization matters because not all clots are the same. In someone with liver cancer, distinguishing a bland (benign) clot from a tumor-invading clot changes treatment completely. Criteria for calling a clot benign include no blood flow within the clot itself on contrast imaging, no mass-like features, and no disruption of the vein walls. When uncertainty remains, a biopsy of the clot tissue can settle the question.7PubMed. Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation CT and MRI play important roles too, particularly for mapping the full extent of clotting and planning interventional procedures.
Survival Rates for Portal Vein Thrombosis
When PVT occurs acutely in a person without cirrhosis and without intestinal damage, the prognosis is generally good.8PubMed Central. Portal vein thrombosis: A concise review The real danger comes when the clot extends into the veins feeding the intestines, which raises the risk of bowel ischemia, a surgical emergency with much worse outcomes.9Techniques in Vascular and Interventional Radiology. Acute Mesenteric and Portal Vein Thrombosis: Etiology, Diagnosis, and Interventional Management
The picture changes substantially when PVT develops in someone who already has cirrhosis. A meta-analysis found that portal vein thrombosis in cirrhotic patients increased the odds of death by about 60% and more than doubled the odds of developing ascites.10PubMed Central. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis This makes intuitive sense: a liver already struggling from scarring has fewer reserves to cope with reduced blood flow. The degree of clot burden matters too. A clot that completely blocks the main portal vein carries a worse prognosis than a partial blockage.
Survival Rates for Budd-Chiari Syndrome
Budd-Chiari syndrome has historically been viewed as a grim diagnosis, but modern stepped treatment strategies have improved outcomes considerably. A large study of BCS patients found overall survival at one, five, and ten years of 82%, 69%, and 62%, respectively.11PubMed. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome Those averages, however, mask wide variation depending on disease severity at diagnosis. Patients with mild disease (low bilirubin, no ascites, normal clotting times) had a five-year survival around 89%, while the most severe group dropped to roughly 42%.
A study focused on patients treated with TIPS, a procedure that creates a new channel inside the liver to reroute blood flow, reported one- and five-year transplant-free survival of 88% and 78%, even in a population where nearly all patients had intermediate or high-risk disease at baseline. For the highest-risk patients specifically, five-year survival with TIPS was about 71%, meaningfully better than the 42% predicted by an older prognostic scoring system.12Gastroenterology. TIPS for Budd-Chiari Syndrome: Long-Term Results and Prognostics Factors in 124 Patients These numbers suggest that aggressive intervention can shift the survival curve upward, especially for people who would otherwise be expected to do poorly.
Anticoagulation as First-Line Treatment
Blood thinners are the cornerstone of treatment for both PVT and BCS, and the evidence supporting them has grown stronger in recent years. A meta-analysis pooling individual patient data from 500 people with cirrhosis and PVT found that anticoagulation reduced the risk of death by about 40%, independent of how severe the clot was or whether the vein reopened.13PubMed. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis That last point is worth emphasizing: even when blood thinners did not fully dissolve the clot, treated patients still lived longer.
A separate systematic review found that anticoagulation more than quadrupled the chances of the portal vein reopening and cut the risk of the clot growing by roughly two-thirds. The key concern with blood thinners in liver patients is bleeding, particularly from esophageal varices. Reassuringly, multiple analyses have found no significant increase in overall bleeding, major bleeding, or variceal bleeding rates compared to untreated patients.14PubMed Central. The Efficacy and Safety of Anticoagulants in the Treatment of Cirrhotic Portal Vein Thrombosis: A Systematic Review and Meta-Analysis Traditional blood thinners like warfarin and low-molecular-weight heparin, as well as newer direct oral anticoagulants, all appear to increase recanalization rates without raising bleeding risk.15PubMed Central. Anticoagulation Favors Thrombus Recanalization and Survival in Patients With Liver Cirrhosis and Portal Vein Thrombosis: Results of a Meta-Analysis
For acute PVT, early anticoagulation is considered essential. The sooner treatment begins, the better the chance of fully restoring blood flow and preventing the chronic complications that come with persistent blockage.2GastroenterologÃa y HepatologÃa (English Edition). Treatment of non-cirrhotic, non-tumoural portal vein thrombosis
Interventional Procedures
When blood thinners alone are not enough, or when patients present with severe portal hypertension symptoms like variceal bleeding and refractory ascites, more invasive approaches come into play. TIPS (transjugular intrahepatic portosystemic shunt) is the most established interventional procedure. In this technique, a radiologist threads a catheter through the jugular vein in the neck, navigates into the liver, and creates a new channel between the portal vein and a hepatic vein, bypassing the blockage and lowering portal pressure.
In a study of 57 cirrhotic patients with PVT, TIPS was successfully placed in 75%. The procedure dramatically reduced variceal rebleeding: one- and five-year rebleeding rates were 10% and 28% in the success group, compared to 43% and 100% in those where TIPS could not be placed. One- and five-year survival rates in the successfully treated group were 86% and 77%.16Journal of Hepatology. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis For patients with completely blocked portal veins where a standard TIPS approach cannot get through, a modified technique using balloon assistance through the liver has shown promise, with no procedure-related complications in one series and maintained blood flow in most patients over a median follow-up of about 16 months.17PubMed. Percutaneous transhepatic balloon-assisted transjugular intrahepatic portosystemic shunt for chronic, totally occluded, portal vein thrombosis with symptomatic portal hypertension
Catheter-directed thrombolysis, where clot-dissolving drugs are delivered directly to the clot through a tube threaded into the affected vein, is another option for acute cases. This approach has been used successfully for both PVT and BCS. In Budd-Chiari patients with clots complicating hepatic vein blockages, catheter-directed thrombolysis combined with balloon widening of the narrowed veins successfully reopened at least one hepatic vein in 13 of the cases treated, without serious complications like major bleeding or lung clots.18PubMed Central. Catheter-directed thrombolytic therapy combined with angioplasty for hepatic vein obstruction in Budd-Chiari syndrome complicated by thrombosis
Liver Transplantation as a Last Resort
Transplantation is reserved for patients who fail all other treatments or who present with sudden, catastrophic liver failure. The step-wise approach to BCS — starting with anticoagulation, escalating to angioplasty or TIPS, and turning to transplant only when those fail — has produced a five-year transplant-free survival rate of about 70% and a five-year overall survival (including those who did receive transplants) of roughly 90%.19PubMed Central. Budd-Chiari syndrome and liver transplantation
A European study of 248 BCS patients who underwent liver transplantation found one-, five-, and ten-year survival rates of 76%, 71%, and 68%. Most deaths occurred in the first three months after surgery, with infection and multi-organ failure accounting for nearly half of fatalities. Graft failure and clotting of the new liver’s blood supply caused another 18% of deaths.20Journal of Hepatology. Liver transplantation for Budd–Chiari syndrome: A European study on 248 patients from 51 centres These numbers reflect a population with the most severe disease, and survival has likely improved since the study period with advances in surgical technique and post-transplant care. Still, transplant carries its own lifelong commitments: immunosuppressive drugs, ongoing monitoring, and a risk of recurrence of the underlying clotting disorder.
Complications That Change the Outlook
The most feared acute complication of PVT is intestinal ischemia. When clotting spreads from the portal vein into the superior mesenteric vein, the blood supply to the intestines can be compromised.21PubMed Central. Clinical Management of Acute Portal/Mesenteric Vein Thrombosis This is a time-sensitive emergency that often requires surgery to remove dead bowel. Diagnosis is frequently delayed because the symptoms, mainly abdominal pain and distension, overlap with many other conditions. The clue is disproportionate pain relative to what the physical exam shows, but even experienced clinicians can miss it.22PubMed Central. Acute intestinal ischaemia from a portal vein thrombosis in a young female smoker on an oral contraceptive
In the chronic phase of PVT, the main complication is the development of varices, enlarged veins that form as blood finds alternative routes around the blockage. In one study, over half of patients who had endoscopic follow-up after acute PVT developed varices, most of them large, within a median of seven months.23Clinical Gastroenterology and Hepatology. Portal Hypertension–Related Complications After Acute Portal vein Thrombosis: Impact of Early Anticoagulation Large varices carry a real risk of sudden, heavy bleeding. This is why endoscopic surveillance is a standard part of follow-up after any portal vein clot, even one that initially responds well to treatment.
Pregnancy With a History of Liver Clots
Pregnancy is a prothrombotic state, meaning the body’s clotting tendency increases naturally. For women who have previously had PVT or BCS, the question of whether pregnancy is safe is understandably anxiety-inducing. A multicenter study of 45 women (12 with BCS, 33 with PVT) across 76 pregnancies found that 76% of first pregnancies resulted in live births, with 79% of those deliveries occurring at term. No maternal deaths occurred. Two women (4%) had variceal bleeding that required treatment during pregnancy, and one developed a pulmonary embolism. Most of the women, 84%, received low-molecular-weight heparin throughout pregnancy.24PubMed Central. Pregnancy outcomes in women with Budd-Chiari syndrome or portal vein thrombosis – a multicentre retrospective cohort study
A separate study of BCS patients who became pregnant found no cases of new thrombosis during any of the pregnancies, though all patients had well-compensated liver disease at the time of conception.25PubMed Central. Outcomes of pregnancy in patients with known Budd-Chiari syndrome The takeaway is that pregnancy can be managed safely in many cases, but it requires close coordination between liver specialists and obstetricians, with anticoagulation throughout pregnancy and careful variceal surveillance.
Liver Clots in Newborns and Children
PVT in newborns is more common than most parents would expect, and it is overwhelmingly linked to umbilical vein catheters, the tubes placed in the umbilical cord stump to deliver fluids and medications in the NICU. One systematic screening study found that 43% of neonates with these catheters had some degree of left portal vein thrombosis, though virtually all cases were clinically silent.26Journal of Perinatology. Systematic ultrasound examinations in neonates admitted to NICU: evolution of portal vein thrombosis The good news is that over 95% of these clots resolved on their own without any blood thinners, simply by removing the catheter. At one year of follow-up, only 4% of infants had a persistent clot.
In another smaller study, PVT was found in about 3% of neonates with umbilical catheters, and clots fully resolved within three to six weeks in the surviving infants.27Pediatric Research. 270 Portal Vein Thrombosis in Neonates with Umbilical Vascular Catheterization When neonatal PVT does persist, the concern is that it can lead to portal hypertension and liver atrophy over time as the child grows.28PubMed Central. Incidence of umbilical vein catheter-associated thrombosis of the portal system: A systematic review and meta-analysis Children with known persistent PVT typically need long-term follow-up with periodic ultrasound and, eventually, evaluation for varices as they get older.
Exercise and Reducing Clotting Risk
For people with chronic liver disease who are at elevated risk for clotting, lifestyle factors like physical activity may matter more than they seem. A randomized trial in patients with fatty liver disease found that a structured exercise program significantly lowered a key clotting promoter called PAI-1 compared to standard care, while also reducing liver fat and improving fitness.29PubMed Central / Wiley Online Library. NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH PAI-1 slows the body’s natural ability to break down clots, so lowering it is a favorable shift. This is a single trial in a specific population, not a blanket prescription, but it adds to the broader evidence that regular exercise supports healthier blood flow and a less clot-prone environment in people with liver conditions.
Beyond exercise, practical management for anyone living with or recovering from a liver clot typically involves ongoing anticoagulation (sometimes indefinitely if the underlying clotting disorder cannot be corrected), regular imaging to monitor for clot changes, endoscopic screening for varices, and attention to the underlying cause. If a myeloproliferative disorder is driving the clotting risk, treating that condition with targeted therapy is crucial to preventing new clots. Staying in regular contact with a hepatologist and a hematologist, rather than relying on a general practitioner alone, tends to produce better outcomes for these patients.